Clinical trials: Venous Thromboembolism, completed
Contraception, Female Contraception
Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks
The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with…
- Trial name
- NCT00331071
- Testing
- Monophasic or triphasic Oral contraceptive tablet, Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Myotonic Dystrophy 1
Venous Thromboembolism in Myotonic Dystrophy Type 1
Investigators identified a high risk of deep vein thrombosis and pulmonary embolism in patients presenting myotonic dystrophy type 1 treated in our hospital, 10 times higher than general population matched on age and sex.
- Trial name
- DM1-VTE (NCT03424460)
- Testing
- Haemostasis tests, Monocytes and megacaryocytes culture and RNA extraction, RNA extraction
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Deep Vein Thrombosis, Venous Thrombosis
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic…
- Conditions
- Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism
- Trial name
- ATTRACT (NCT00790335)
- Testing
- Recombinant tissue plasminogen activator (rt-PA)
- Where
- 56 sites in United States
- Volunteers
- 692 people
- Sponsor
- Washington University School of Medicine
Prophylaxis of Venous Thromboembolism
PK of Rivaroxaban in Bariatric Patients - Extension
Aim of this clinical Trial is the assessment of rivaroxaban PK/PD parameters in patients 6-8 months after bariatric surgery
- Trial name
- NCT02832947
- Testing
- Rivaroxaban 10 mg
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Thrombophlebitis
POST (Prospective Observational Superfial Thrombophlebitis)
We performed a national cross-sectional and prospective large epidemiological cohort study in patients with ST. Office- and hospital-based vascular medicine French practitioners enrolled all consecutive patients with a…
- Trial name
- POST (NCT00818688)
- Testing
- compression ultrasonography at 3 months
- Where
- 5 sites in France
- Volunteers
- 844 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Pulmonary Embolism and Thrombosis
An International Pulmonary Embolism Registry Using EKOS
This registry is designed to understand acoustic pulse thrombolysis (APT) treatment regimens used as standard of care globally for pulmonary embolism.
- Trial name
- KNOCOUT PE (NCT03426124)
- Testing
- EkoSonic Endovascular System with thrombolytic
- Where
- 80 sites in United States, Austria and 6 more
- Volunteers
- 1,480 people
- Sponsor
- Boston Scientific Corporation
Venous Thromboembolism
Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Korea and Taiwan (ETNA-VTE-KOR-TWN)
According to current guidelines, duration of anticoagulant treatment after a venous thromboembolic event varies from 3 months to indefinite treatment depending on the estimated risks of venous thromboembolism (VTE) recurrence and…
- Trial name
- NCT02952599
- Testing
- Edoxaban
- Where
- 19 sites in South Korea, Taiwan
- Volunteers
- 352 people
- Sponsor
- Daiichi Sankyo
Neoplasms
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein…
- Trial name
- NCT02555878
- Testing
- Rivaroxaban
- Where
- 151 sites in United States, Belgium and 8 more
- Volunteers
- 841 people
- Sponsor
- Janssen Research & Development, LLC
Prophylaxis of Venous Thromboembolism
Rivaroxaban in Bariatric Surgery
Until now there ist no systematic investigation of the pharmacokinetic parameters of Rivaroxaban in obese patient undergoing bariatric surgery.
- Trial name
- NCT02438098
- Testing
- Rivaroxaban 10 mg
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Thromboembolism, Arterial
Fiix-prothrombin Time for Monitoring Warfarin
Experiments suggest that during treatment with vitamin K antagonists (VKA) the activity of coagulation factors (F) II and X better reflect anticoagulation than does FVII.
- Conditions
- Thromboembolism, Arterial, Venous
- Trial name
- Fiix (NCT01565239)
- Testing
- Fiix prothrombin time
- Where
- Iceland
- Volunteers
- 1,156 people
- Sponsor
- Landspitali University Hospital
Cerebral Vein Thrombosis
Rivaroxaban vs. Warfarin in CVT Treatment
Cerebral venous thrombosis (CVT) is an uncommon venous-type of stroke tends to affect younger patients with somewhat different risk factors and much better outcome compared to arterial strokes.
- Trial name
- RWCVT (NCT04569279)
- Testing
- Rivaroxaban, Warfarin
- Where
- Syria
- Volunteers
- 71 people
- Sponsor
- Damascus University
Pulmonary Embolism, Deep Vein Thrombosis
SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis
Patients diagnosed with pulmonary embolism (blood clot in the lung) or deep vein thrombosis (blood clot in a leg vein) are at risk for these blood clots to reoccur.
- Trial name
- NCT00071279
- Testing
- SR34006 (idraparinux sodium) Injection
- Where
- 65 sites in United States, Australia and 18 more
- Volunteers
- 1,215 people
- Sponsor
- Sanofi
Venous Thromboembolism
An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism
This is an observational study in which only data will be collected from children with venous thromboembolism who are prescribed rivaroxaban or warfarin by their doctors.
- Trial name
- NCT06278051
- Testing
- Rivaroxaban granules for oral suspension, Warfarin
- Where
- 2 sites in Japan
- Volunteers
- 320 people
- Sponsor
- Bayer
Venous Thromboembolism
Prevalence of Gynecological Pathologies and Use of Hormonal Treatments in Women Hospitalized for a Venous Thromboembolic Episode
The incidence of venous thrombosis (venous thromboembolic disease: VTE) in women of childbearing age in France is in the order of 0.3 to 0.5 / 1000 women / year.
- Trial name
- THROMBO-GYN (NCT04920487)
- Where
- France
- Volunteers
- 201 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Deep Vein Thrombosis, Pulmonary Embolism
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
The purpose of this study is to learn whether apixaban can prevent the blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism) that sometimes occur after hip replacement surgery and to learn how apixaban…
- Trial name
- NCT00423319
- Testing
- Enoxaparin, Apixaban
- Where
- 143 sites in United States, Argentina and 19 more
- Volunteers
- 5,407 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism, Covid19
COVID-19 and Venous Thromboembolism Risk
Coronavirus disease 2019 (Covid-19) is now a leading cause of death among U.S. adults. In addition to profound respiratory and multi-organ failure, hypercoagulable states and venous thromboembolism (VTE) have been increasingly…
- Trial name
- NCT04569344
- Testing
- Laboratory test positive for SARS-CoV-2 virus
- Where
- 2 sites in United States
- Volunteers
- 398,530 people
- Sponsor
- University of California, San Francisco
Venous Thromboembolism
BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery
To determine the therapeutic window of BIBR 1048 in order to select doses for further studies in the development plan. Twice daily regimen will be tested for most dose levels and once daily administration will also be evaluated…
- Trial name
- NCT02170701
- Testing
- BIBR 1048
- Volunteers
- 289 people
- Sponsor
- Boehringer Ingelheim
Heavy Menstrual Bleeding
Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants
Prospective comparison of the incidence of heavy menstrual bleeding (HMB) in women of reproductive age treated with direct oral anticoagulants (DOACs)
- Trial name
- NCT04477837
- Testing
- Apixaban 5 MG, Rivaroxaban 20 MG, Edoxaban 60 MG
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Venous Thromboembolism
Effect of the Genotype on Postoperative DVT
Postoperative Venous Thromboembolism Events (VTE) constitute a major source of morbidity and mortality after surgery. The aim of this study was to investigate whether commonly occurring Single Nucleotide Polymorphisms (SNPs) are…
- Trial name
- NCT04940377
- Where
- Denmark
- Volunteers
- 502,505 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Venous Thromboembolism
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
The study drug, BAY59-7939, is a new drug currently being tested in the prevention of VTE. It directly inhibits factor Xa, a blood component in the pathway which leads to coagulation (clotting of blood cells).
- Trial name
- NCT00402467
- Testing
- Rivaroxaban (BAY59-7939), Rivaroxaban, (BAY59-7939), Enoxaparine
- Where
- 36 sites in United States, Canada
- Volunteers
- 613 people
- Sponsor
- Bayer